Cargando…

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Detalles Bibliográficos
Autores principales:	Broucek, Joseph R, Hughes, Tasha, Huelsmann, Erica J, Poshepny, Joseph L, Ruby, Carl E, Zloza, Andrew, Kaufman, Howard L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991168/ http://dx.doi.org/10.1186/2051-1426-1-S1-P70

Ejemplares similares

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
por: Kohlhapp, Frederick J, et al.
Publicado: (2015)

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
por: Kim, Dae Won, et al.
Publicado: (2014)

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
por: Kaufman, Howard L, et al.
Publicado: (2014)

Single-step nanoparticle antigen presentation system for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015)

Erratum: Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2016)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

The impact of age on a mitoxantrone-based tumor vaccine
por: Stonewall, Keven, et al.
Publicado: (2013)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
por: Lussier, Danielle M, et al.
Publicado: (2015)

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
por: Foy, Susan P., et al.
Publicado: (2016)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Interleukin‐1 blockade treatment decreasing cardiovascular risk
por: Zheng, Zi‐Heng, et al.
Publicado: (2019)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mim9s8aiku1cenp5jpikhph62k